基因表达特征联合终末期肝病模型评分预测重症酒精性肝炎患者生存
研究纳入比利时71例接受糖皮质激素治疗的重症酒精性肝炎患者作为推导队列,整合123个基因表达特征与MELD评分构建gs-MELD评分。该评分在比利时和瑞士48例验证队列1及美国20例验证队列2中均能区分90天和180天生存良好与不良的患者,且验证队列1中优于其他临床模型。
要点
- gs-MELD评分整合123个基因表达特征与MELD评分,可区分重症酒精性肝炎患者90天和180天生存良好与不良。
- 推导队列中,gs-MELD评分将患者分为生存不良组(90天生存率29%、180天生存率26%)与生存良好组(90天生存率76%、180天生存率65%)(P<.001)。
- 验证队列1中,gs-MELD评分预测90天生存的时依ROC曲线下面积为0.86(95%CI 0.73-0.99),180天为0.83(95%CI 0.71-0.96)。
核心结论
- 整合基线肝脏基因表达模式与MELD评分构建的gs-MELD评分系统,可识别接受或不接受糖皮质激素治疗的重症酒精性肝炎患者中90天和180天最可能生存与最不可能生存的患者。
研究设计与样本
- 推导队列为2006年7月至2013年12月比利时布鲁塞尔连续71例接受糖皮质激素治疗的重症酒精性肝炎患者的固定肝活检样本,用微阵列分析基因表达并收集180天临床数据。
- 验证队列1为2010年3月至2015年2月比利时和瑞士医院连续48例接受糖皮质激素治疗的重症酒精性肝炎患者的肝活检。
- 验证队列2为2012年1月至2015年5月美国20例患者的肝活检,其中9例接受糖皮质激素治疗。
主要发现
- 推导队列中,gs-MELD评分将患者分为生存不良组(90天生存率29%、180天生存率26%)与生存良好组(90天生存率76%、180天生存率65%)(P<.001)。
- 验证队列1中,gs-MELD评分区分生存不良组(90天生存率43%)与生存良好组(90天生存率96%)(P<.001),并区分180天生存不良组(生存率34%)与生存良好组(生存率84%)(P<.001)。
- 验证队列1中,gs-MELD评分预测90天生存的时依ROC曲线下面积为0.86(95%CI 0.73-0.99),预测180天生存为0.83(95%CI 0.71-0.96)。
- 验证队列1中,该评分在预测重症酒精性肝炎患者生存方面优于其他临床模型。
- 验证队列2中,gs-MELD评分区分90天生存不良组(生存率12%)与生存良好组(生存率100%)(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with severe alcoholic hepatitis (AH) have a high risk of death within 90 days. Corticosteroids, which can cause severe adverse events, are the only treatment that increases short-term survival. It is a challenge to predict outcomes of patients with severe AH. Therefore, we developed a scoring system to predict patient survival, integrating baseline molecular and clinical variables. METHODS: We obtained fixed liver biopsy samples from 71 consecutive patients diagnosed with severe AH and treated with corticosteroids from July 2006 through December 2013 in Brussels, Belgium (derivation cohort). Gene expression patterns were analyzed by microarrays and clinical data were collected for 180 days. We identified gene expression signatures and clinical data that are associated with survival without liver transplantation at 90 and 180 days after initiation of corticosteroid therapy. Findings were validated using liver biopsies from 48 consecutive patients with severe AH treated with corticosteroids, collected from March 2010 through February 2015 at hospitals in Belgium and Switzerland (validation cohort 1) and in liver biopsies from 20 patients (9 received corticosteroid treatment), collected from January 2012 through May 2015 in the United States (validation cohort 2). RESULTS: We integrated data on expression patterns of 123 genes and the model for end-stage liver disease (MELD) scores to assign patients to groups with poor survival (29% survived 90 days and 26% survived 180 days) and good survival (76% survived 90 days and 65% survived 180 days) (P < .001) in the derivation cohort. We named this assignment system the gene signature-MELD (gs-MELD) score. In validation cohort 1, the gs-MELD score discriminated patients with poor survival (43% survived 90 days) from those with good survival (96% survived 90 days) (P < .001). The gs-MELD score also discriminated between patients with a poor survival at 180 days (34% survived) and a good survival at 180 days (84% survived) (P < .001). The time-dependent area under the receiver operator characteristic curve for the score was 0.86 (95% confidence interval 0.73-0.99) for survival at 90 days, and 0.83 (95% confidence interval 0.71-0.96) for survival at 180 days. This score outperformed other clinical models to predict survival of patients with severe AH in validation cohort 1. In validation cohort 2, the gs-MELD discriminated patients with a poor survival at 90 days (12% survived) from those with a good survival at 90 days (100%) (P < .001). CONCLUSIONS: We integrated data on baseline liver gene expression pattern and the MELD score to create the gs-MELD scoring system, which identifies patients with severe AH, treated or not with corticosteroids, most and least likely to survive for 90 and 180 days.
引用
- Trépo E, Goossens N, Fujiwara N, et al. Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2017. PMID: 29158192. doi:10.1053/j.gastro.2017.10.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。